United Therapeutics (UTHR) Tops Q2 EPS by 82c

United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.98, $0.82 better than the analyst estimate of $3.16. Revenue for the quarter came in at $444.5 million versus the consensus estimate of $368.58 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
• CalPrivate Bank names Andra Frazier as chief credit officer